macro

B Riley rates Praxis a new Buy ahead of possible approval for two therapies

B Riley has issued a new Buy rating on Praxis shares as the company nears potential approval of two therapies, according to Seeking Alpha.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Analysts at B Riley have assigned a Buy rating to Praxis shares, according to Seeking Alpha. The report links the new recommendation to the possible approval of two of the company's therapies.

The Seeking Alpha piece itself carries only a general disclaimer stating that its content is for information purposes, that it offers no personal investment advice, and that the publisher is not a licensed broker or investment bank.

why it matters

A single broker's rating is a routine event, but for biotech companies, regulatory decisions on new drugs usually move shares more than analyst opinions do. For the market, the regulatory process itself remains the key factor.

tags

instruments

Praxis Precision Medicines

sources

  1. Praxis a new Buy at B Riley on cusp of potential approval for two therapies — Seeking Alpha, 20 November 2026 at 18:12 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗